VSTM
VSTM clinical trials: Verastem, Inc.
Every trial on ClinicalTrials.gov where Verastem, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 50
- Trials linked
- 27
- As lead sponsor
- 23
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
VSTM on the catalyst calendar · VSTM registry changes
- Primary completion Jun 2027Sponsor estimatePhase 2NCT07659795A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerVerastem, Inc. · Colorectal CancerRecruitingVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 2NCT07659782A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung CancerVerastem, Inc. · Non-Small Cell Lung CancerRecruitingVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 2NCT07644559A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerVerastem, Inc. · Pancreatic Ductal Adenocarcinoma (PDAC)RecruitingVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 1/Phase 2NCT07020221A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsVerastem, Inc. · Pancreatic Ductal AdenocarcinomaRecruitingVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 15, 2028Sponsor estimatePhase 3NCT06072781A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerVerastem, Inc. · Low Grade Serous Ovarian CancerRecruitingVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2027Sponsor estimatePhase 2NCT07747506Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)Verastem, Inc. · Low Grade Ovarian Serous AdenocarcinomaNot yet recruitingVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 15, 2026ActualPhase 1/Phase 2NCT05375994Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC PatientsVerastem, Inc. · Non Small Cell Lung CancerCompletedVSTMLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2026Sponsor estimatePhase 1/Phase 2NCT05074810Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsVerastem, Inc. · Non Small Cell Lung CancerActive, not recruitingVSTMLeadAMGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2025Sponsor estimatePhase 2NCT06682572A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese PatientsVerastem, Inc. · Low Grade Serous Ovarian CancerActive, not recruitingVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2026Sponsor estimatePhase 1/Phase 2NCT05669482Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic CancerVerastem, Inc. · KRAS Activating MutationActive, not recruitingVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2024ActualPhase 2NCT04625270A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a...Verastem, Inc. · Low Grade Ovarian Serous AdenocarcinomaActive, not recruitingVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 19, 2019ActualPhase 2NCT02004028Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsVerastem, Inc. · Malignant Pleural MesotheliomaTerminatedVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 29, 2023ActualPhase 2NCT04620330A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung CancerVerastem, Inc. · Non Small Cell Lung CancerCompletedVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 12, 2022ActualPhase 1NCT05187169Food Effect of VS-6766 in Healthy Adult SubjectsVerastem, Inc. · Food EffectCompletedVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 28, 2018ActualPhase 1NCT02943317Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With...Verastem, Inc. · Epithelial Ovarian CancerTerminatedVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2017ActualPhase 1NCT02651727Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer SubjectsVerastem, Inc. · Pancreatic CancerTerminatedVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2017ActualPhase 1NCT01849744Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic MalignanciesVerastem, Inc. · Non Hematologic CancersTerminatedVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 23, 2015ActualPhase 1NCT01778803Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian CancerVerastem, Inc. · Ovarian CancerCompletedVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2016ActualPhase 2NCT01951690Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung CancerVerastem, Inc. · Non Small Cell Lung CancerCompletedVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2015ActualPhase 1NCT02913716A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male SubjectsVerastem, Inc. · Healthy SubjectsCompletedVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2015ActualPhase 1NCT02372227A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant MesotheliomaVerastem, Inc. · Relapsed Malignant MesotheliomaTerminatedVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2016Sponsor estimatePhase 1NCT02215629Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic LeukemiaVerastem, Inc. · Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016ActualPhase 1NCT01991938Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or LymphomaVerastem, Inc. · Non Hematologic CancersTerminatedVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 9, 2014ActualPhase 1NCT01943292Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic MalignanciesVerastem, Inc. · Non Hematologic CancersCompletedVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2016ActualPhase 2NCT01870609Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural MesotheliomaVerastem, Inc. · Malignant Pleural MesotheliomaTerminatedVSTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 25 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner